Century Therapeutics Inc (NASDAQ: IPSC) kicked off on Monday, down -5.54% from the previous trading day, before settling in for the closing price of $0.54. Over the past 52 weeks, IPSC has traded in a range of $0.34-$2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 18.46% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 86.85%. With a float of $41.50 million, this company’s outstanding shares have now reached $86.32 million.
In an organization with 150 employees, it is important to assess its efficiency.
Century Therapeutics Inc (IPSC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Century Therapeutics Inc is 51.96%, while institutional ownership is 23.59%. The most recent insider transaction that took place on Aug 18 ’25, was worth 17,522. Before that another transaction happened on Aug 04 ’25, when Company’s SVP Finance & Operations sold 296 for $0.53, making the entire transaction worth $158. This insider now owns 405,686 shares in total.
Century Therapeutics Inc (IPSC) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.37 earnings per share (EPS), higher than consensus estimate (set at -0.45) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.41% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Take a look at Century Therapeutics Inc’s (IPSC) current performance indicators. Last quarter, stock had a quick ratio of 10.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.74 million. That was better than the volume of 0.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 40.91%.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 49.03%, which indicates a significant increase from 29.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0424 in the past 14 days, which was higher than the 0.0418 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5682, while its 200-day Moving Average is $0.7551. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $0.5508. Second resistance stands at $0.5903. The third major resistance level sits at $0.6139. If the price goes on to break the first support level at $0.4877, it is likely to go to the next support level at $0.4641. Assuming the price breaks the second support level, the third support level stands at $0.4246.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
The company with the Market Capitalisation of 44.16 million has total of 86,389K Shares Outstanding. Its annual sales at the moment are 6,590 K in contrast with the sum of -126,570 K annual income. Company’s last quarter sales were recorded 109,160 K and last quarter income was 76,560 K.
